News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Resistance news

Show

From To
Changing treatment
Drug-Resistance Mutations May Curb Efficacy of Dolutegravir-Based Regimens in Zimbabwe Teens With HIV

"Public health (officials) should definitely be aware of the implications of drug resistance mutations conferring resistance to tenofovir and/or lamivudine on the activity, efficacy and durability of DTG in such a country, knowing that at present, individual- level HIV drug resistance testing in low and middle income countries (LMICs) is rare and that data are lacking on DTG use in settings with limited or no viral load monitoring."

Published
07 July 2019
From
Medscape (free registration required)
Resistance
Genotype Testing at HIV Diagnosis Provides No Benefit

For the majority of people with HIV in the US, the current treatment guidelines recommend an integrase strand inhibitor paired with an NRTI as first-line ART. Therefore, baseline genotype results currently guide the choice of initial NRTI pair, given transmitted NRTI resistance (NRTI-R). With this evolution of HIV treatment, the role and value of baseline genotype testing has become uncertain. This study determined the clinical and economic value of baseline genotype testing for people newly diagnosed with HIV in the US.

Published
25 June 2019
From
Infectious Disease Advisor
Treatment-experienced people
ART for treatment-experienced people with virological failure can omit NRTIs if three active drugs available

Treatment for HIV-positive individuals with persistent viral replication despite therapy with multiple regimens is effective and safe over two years when it omits nucleoside reverse transcriptase inhibitors

Published
13 June 2019
By
Michael Carter
Health monitoring in resource-limited settings
Significant health gains from faster switching to second-line ART in sub-Saharan Africa

Switching to second-line antiretroviral therapy (ART) after a single viral load measurement above 1000 copies/ml has the potential to save lives, avert a significant burden of AIDS-related illnesses

Published
29 May 2019
By
Michael Carter
Opportunistic infections
A Mysterious Infection, Spanning the Globe in a Climate of Secrecy

The rise of Candida auris embodies a serious and growing public health threat: drug-resistant germs. Over the last five years, it has hit a neonatal unit in Venezuela, swept through a hospital in Spain, forced a prestigious British medical center to shut down its intensive care unit, and taken root in India, Pakistan and South Africa.

Published
08 April 2019
From
New York Times
Changing treatment
Dolutegravir-based second-line ART achieves excellent virological outcomes even in the presence of resistance to recycled NRTIs

Virological response rates were excellent among patients receiving second-line antiretroviral therapy (ART) based on dolutegravir, even when regimens included a nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) to which there

Published
13 March 2019
By
Michael Carter
Treatment-experienced people
Can high-dose dolutegravir be a rescue therapy?

A small study in Italy found that high doses of the powerful integrase inhibitor dolutegravir (Tivicay, and also found in Juluca and Triumeq) can be used as a key part of rescue therapy for people with HIV that has extensive drug resistance to treatment. When doctors doubled the dose typically prescribed for treatment-experienced people to 100 mg twice daily, they found that high-dose dolutegravir was well absorbed with no occurrence of neuropsychiatric or serious side effects.

Published
12 March 2019
From
CATIE
Resistance
One in six South Africans drug resistant before starting HIV treatment

One in six people not on treatment in a large South African household survey already had drug-resistant HIV and more than half of those on treatment had

Published
11 March 2019
By
Keith Alcorn
PrEP science
How many people who have used PrEP get HIV the same year? New York study finds out

One question often asked about pre-exposure prophylaxis (PrEP) use is how frequently people start PrEP while unknowingly having HIV, often because they have acquired it so recently

Published
07 March 2019
By
Gus Cairns
Resistance
South Africa reports successful third-line HIV treatment programme

People with resistance to first- and second-line antiretroviral drugs can still achieve high rates of viral suppression in the first year on third-line regimens according to a

Published
04 January 2019
By
Esther Nakkazi
← First12345...39Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.